The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
Open accessAbstract
Various lines of evidence indicate the presence of progressive pathophysiological processes occurring within the brains of patients with schizophrenia. By modulating chemical neurotransmission, antipsychotic drugs may influence a variety of functions regulating neuronal resilience and viability and have the potential for neuroprotection. This article reviews the current literature describing preclinical and clinical studies that evaluate the efficacy of antipsychotic drugs, their mechanism of action and the potential of first- and second-generation antipsychotic drugs to exert effects on cellular processes that may be neuroprotective in schizophrenia. The evidence to date suggests that although all antipsychotic drugs have the ability to reduce psychotic symptoms via D2 receptor antagonism, some antipsychotics may differ in other pharmacological properties and their capacities to mitigate and possibly reverse cellular processes that may underlie the pathophysiology of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parallel organization of functionally segregated circuits linking basal ganglia and cortex
Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.09.030186.002041 · Cited by 8,527
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationRequirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 2×
“…neurogenesis has been consistently observed with both pharmacological and nonpharmacological antidepressant therapies (Madsen et al., 2000; Malberg et al., 2000) and seems to be functionally important in the behavioral effects of antidepressant drugs observed in mice (Santarelli et al., 2003).”
BackgroundSelf-citationThe Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 3×
“The NMDA receptor is a heteromeric assembly of an obligatory NR1 subunit (eight distinct isoforms) and a combination of NR2A, NR2B, NR2C, NR2D, NR3A, and NR3B subunits (Dingledine et al., 1999; Millan, 2005).”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Regulation of neuronal survival by the serine-threonine protein kinase Akt
Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., & Greenberg, M. E. (1997) · Science · doi:10.1126/science.275.5300.661 · Cited by 2,436
Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor
Majewska, M. D., Harrison, N. L., Schwartz, R. D., Barker, J. L., & Paul, S. M. (1986) · Science · doi:10.1126/science.2422758 · Cited by 2,225
Learning enhances adult neurogenesis in the hippocampal formation
Gould, E., Beylin, A., Tanapat, P., Reeves, A., & Shors, T. J. (1999) · Nature Neuroscience · doi:10.1038/6365 · Cited by 2,157
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 2×
“…Angelucci et al., 2000b Haloperidol (1 mg/kg, 28 days) BDNF/HP Decreased Lipska et al., 2001 Haloperidol (2 mg/kg, 21 days) BDNF/HP, FrCtx Decreased Nibuya et al., 1995 Haloperidol (1 mg/kg, 28 days) BDNF/HP Decreased Bai et al., 2003 Haloperidol (1 mg/kg, 19 days) BDNF/HP Decreased Chlan-Fourney…”
InfluentialSelf-citationBasal ganglia and cerebellar loops: motor and cognitive circuits
Middleton, F. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00040-5 · Cited by 1,940
Cited by
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Boksa, P. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.03.005 · Cited by 603
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Self-citationGeneral Anesthesia and Altered States of Arousal: A Systems Neuroscience Analysis
Brown, E. N., Purdon, P. L., & Van Dort, C. J. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153200 · Cited by 539
Lui, S., Li, T., Deng, W., Jiang, L., Wu, Q., Tang, H., Yue, Q., Huang, X., Chan, R. C., Collier, D. A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.84 · Cited by 365
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318070-000000000-00000 · Cited by 330
HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity
Kurita, M., Holloway, T., García-Bea, A., Kozlenkov, A., Friedman, A. K., Moreno, J. L., Heshmati, M., Golden, S. A., Kennedy, P. J., Takahashi, N., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3181 · Cited by 285
Juster, R.-P., Bizik, G., Picard, M., Arsenault-Lapierre, G., Sindi, S., Trepanier, L., Marin, M.-F., Wan, N., Sekerovic, Z., Lord, C., et al. (2011) · Development and Psychopathology · doi:10.1017/s0954579411000289 · Cited by 268
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Li, P., L. Snyder, G., & E. Vanover, K. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160608084834 · Cited by 266
Tracing the development of psychosis and its prevention: what can be learned from animal models
Piontkewitz, Y., Arad, M., & Weiner, I. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.019 · Cited by 108
Citrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63
Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in rats
Nasrallah, H. A., Hopkins, T., & Pixley, S. K. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.075 · Cited by 52
Calabrese, F., Luoni, A., Guidotti, G., Racagni, G., Fumagalli, F., & Riva, M. A. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2900-0 · Cited by 43
Metadata
- Authors
- Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X.-M., Mahadik, S. P., Duman, R. S., Porter, J. H., Modica-Napolitano, J. S., Newton, S. S., & Csernansky, J. G.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 60
- Issue
- 3
- Pages
- 358-403
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2128717592
- Cited by
- 220
- References
- 61
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.